Ann: Breakthrough Zantrene Heart Protection Discovery, page-118

Two reasons

1. The market for anthracyclines is already proven. We won’t be trying to establish a totally new treatment approach (e.g FTO), just make the existing treatment work better with less side effects. This is a much, much easier commercial prospect.

2. The in vitro models map to the clinical data very well. This point is subtle, but super important. The in vitro cell models were built to replicate what happens in patients in the clinic. You can map one-to-one the response you see in patients to the cell cultures. Unlike with FTO, anthracyclines are very, very well studied and so we know a huge amount how laboratory results translate into the clinic. I wish there was an easy way of explain this to non-scientists, but it is one of the reasons I am so amazed by these results.